Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProMIS Neurosciences Inc. (Nasdaq: PMN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, proxy statements and other key documents. ProMIS is a clinical-stage biotechnology company focused on antibody and vaccine candidates targeting toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases, and its filings offer detailed insight into corporate actions, governance and clinical program updates.
Through recent Form 8-K filings, ProMIS has reported material events such as the implementation of a one-for-twenty-five reverse stock split of its common shares, effective November 28, 2025, and subsequent notification from Nasdaq that the company regained compliance with the $1.00 minimum bid price requirement. Other 8-Ks describe the recommendation of an independent Data and Safety Monitoring Board to advance the PRECISE-AD Phase 1b trial of PMN310 to the final dose escalation cohort, the establishment of an at-the-market offering program, and the appointment and compensation of directors and executives.
The company’s definitive proxy statement on Schedule 14A outlines matters submitted to shareholders, including authorization of the share consolidation and procedures for a virtual special meeting. These materials provide information on share structure proposals, voting results and corporate governance practices. Additional filings reference press releases reporting quarterly financial results, which are incorporated by reference into Item 2.02 of Form 8-K.
On Stock Titan, ProMIS filings are updated in line with EDGAR and can be reviewed alongside AI-powered summaries that explain the significance of each document. Investors can quickly see how reverse stock split mechanics, Nasdaq listing compliance, at-the-market offerings, and clinical trial milestones are described in official filings. Over time, this page will also aggregate annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 as they are filed, helping users track both the scientific and capital markets dimensions of PMN’s development.
PROMIS NEUROSCIENCES INC. has a Schedule 13G/A reporting that Armistice Capital, LLC and Steven Boyd beneficially own 504,672 common shares, representing 0.93% of the class. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., exercises voting and investment power over the shares held by the Master Fund; the Master Fund is the direct holder and disclaims beneficial ownership by virtue of the Investment Management Agreement.
The Schedule is a joint filing by Armistice Capital and Steven Boyd executed 02/17/2026 and lists shared voting and dispositive power consistent with the reported position.
ProMIS Neurosciences Inc. received an updated ownership report showing that Great Point Partners, LLC, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl beneficially own 409,648 common shares, representing 9.99% of the outstanding class.
The filing explains that this stake includes 238,894 common shares issuable upon exercise of various warrants, which are subject to a 9.99% Beneficial Ownership Cap that limits how many shares can be exercised. The report details warrants held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd. and notes that Great Point, Dr. Jay and Ms. Nordahl may be deemed beneficial owners through their roles, while they disclaim beneficial ownership beyond their pecuniary interests. The reporting group certifies the securities are not held to change or influence control of ProMIS.
ProMIS Neurosciences Inc. disclosed that investment entities affiliated with Trails Edge Capital Partners and Ortav Yehudai have filed a Schedule 13G reporting a 9.9% beneficial stake in its common shares as of February 3, 2026.
The filing shows beneficial ownership of 933,477 shares, consisting of 557,103 common shares and 376,374 shares underlying warrants, held through Trails Edge Biotechnology Master Fund. An additional 180,729 warrant shares are excluded due to a 9.99% ownership cap. Ownership percentages are based on 8,967,740 ProMIS common shares outstanding. The filers certify the holdings are not for changing or influencing control.
ProMIS Neurosciences Inc. received a Schedule 13G filing showing that Deep Track Capital and related entities beneficially own 902,561 common shares, representing 9.99% of the company’s common stock as of February 6, 2026.
The filing explains that this percentage is calculated using 9,034,646 common shares, combining 2,152,444 shares outstanding as of November 12, 2025, 6,815,296 shares issued on January 30, 2026, and 66,906 shares that could be converted up to a 9.99% maximum ownership cap.
The beneficial ownership includes 835,655 warrants that are exercisable into common shares but are subject to a 9.99% “Maximum Percentage” limitation, so exercises cannot push Deep Track’s collective holdings above that threshold.
ProMIS Neurosciences director and Chief Scientific Officer Neil Cashman reported an indirect purchase of 4,122 common shares at $12.13 per share through Research Capital Corporation, along with warrants to buy 4,122 additional common shares. These securities were acquired on February 3, 2026 under a Securities Purchase Agreement with selected investors.
The warrants to purchase common shares have an exercise price of $14.40 per share and are exercisable immediately. They will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from single ascending dose cohorts of PMN310. The filing also notes that common share figures reflect a one-for-twenty-five reverse split completed on November 28, 2025.
ProMIS Neurosciences Chief Development Officer Johanne Kaplan acquired equity on February 3, 2026. Kaplan bought 2,060 common shares at $12.13 per share and received warrants to purchase 2,060 additional common shares, also priced at $12.13 per common share and warrant under a Securities Purchase Agreement with selected investors.
After the transaction, Kaplan beneficially owned 2,312 common shares directly. The warrants have an exercise price of $14.40 per common share and become exercisable on February 3, 2026. They will expire on the earlier of February 3, 2031 or within 60 days after public announcement of topline data from PMN310 single ascending dose cohorts.
ProMIS Neurosciences Inc. insider transaction: Chief Executive Officer and director Neil K. Warma acquired 6,183 common shares of ProMIS Neurosciences Inc. on February 3, 2026 at a price of $12.13 per share. He also received warrants to purchase 6,183 common shares at an exercise price of $14.40 per share.
The warrants become exercisable on February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from PMN310 single ascending dose cohorts.
ProMIS Neurosciences principal accounting officer Max A. Milbury reported purchasing additional equity in the company. On February 3, 2026, he acquired 6,595 common shares of ProMIS Neurosciences Inc. at a purchase price of $12.13 per share under a Securities Purchase Agreement with selected investors.
He also received common share purchase warrants to buy 6,595 additional common shares. These warrants are exercisable starting February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from cohorts treated with single ascending doses of PMN310. Following the transaction, he beneficially owned 8,409 common shares and 6,595 warrants, all held directly.
ProMIS Neurosciences director Patrick D. Kirwin reported buying additional shares and warrants in the company. On February 3, 2026, he acquired 3,050 common shares and warrants to purchase 3,050 common shares under a Securities Purchase Agreement at $12.13 per share and warrant.
Following the transaction, he directly holds 5,135 common shares and warrants for 3,050 common shares with a $14.4 exercise price. He also indirectly beneficially owns 1,653 common shares through Patrick D. Kirwin Professional Corp and 305 common shares through his spouse. The filing notes a one-for-twenty-five reverse split completed on November 28, 2025, and states the warrants expire on the earlier of February 3, 2031 or within 60 days after topline PMN310 single ascending dose data is publicly announced.
ProMIS Neurosciences Inc. large shareholder group led by Fan Yu filed an amended Schedule 13D showing updated ownership after a recent equity financing. The reporting persons collectively report beneficial ownership of 1,644,397 common shares, representing 17.0% of ProMIS’s outstanding common shares.
The filing reflects the closing of an Offering on February 3, 2026, under a Securities Purchase Agreement. Ally Bridge MedAlpha Master Fund L.P. bought 164,881 common shares and warrants for 164,881 shares for $2,000,006.53. ABG V-SIV IX Limited bought 329,760 shares and matching warrants for $3,999,988.80, and ABG V-SIV X Limited bought 206,100 shares and matching warrants for $2,499,993.
The ownership percentages are based on 8,967,693 common shares outstanding immediately after the Offering, and include both currently held shares and shares issuable upon warrant exercise subject to stated limitations. The disclosure also notes a 1-for-25 reverse stock split completed on November 28, 2025.